cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Denali Therapeutics Inc
11 own
5 watching
Current Price
$20.73
$-1.39
(-6.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,534.04M
52-Week High
52-Week High
33.31000
52-Week Low
52-Week Low
14.56000
Average Volume
Average Volume
1.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
224.4045
iconMarket Capitalization2,534.04M
icon52-Week High33.31000
icon52-Week Low14.56000
iconAverage Volume1.01M
iconDividend Yield--
iconP/E Ratio224.4045
What does the Denali Therapeutics Inc do?
N/A
Read More
How much money does Denali Therapeutics Inc make?
News & Events about Denali Therapeutics Inc.
Zolmax
11 months ago
Denali Therapeutics Inc. (NASDAQ:DNLI Free Report) Director Vicki L. Sato sold 1,666 shares of the companys stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $29.84, for a total value of $49,713.44. Following the completion of the transaction, ...
Globe Newswire
1 year ago
Program uses Denalis Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.(Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) ...
Benzinga
1 year ago
Latest Ratings for DNLI DateFirmActionFromTo Jan 2022Morgan StanleyMaintainsOverweight Sep 2021OppenheimerInitiates Coverage OnOutperform Aug 2021Morgan StanleyMaintainsOverweight View More Analyst Ratings for DNLI View the Latest Analyst Ratings read more...
Globe Newswire
1 year ago
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR pharmacodynamic data, along with preclinical data, are consistent with extensive CNS distribution and ...
Zolmax
1 year ago
Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Stock analysts at Wedbush increased their Q1 2023 earnings per share (EPS) estimates for shares of Denali Therapeutics in a research report issued on Tuesday, February 28th. Wedbush analyst L. Chico now expects that the company will earn ($0.69) per ...
Frequently Asked Questions
Frequently Asked Questions
What is Denali Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Denali Therapeutics Inc shares?
plus_minus_icon
How can I buy Denali Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Denali Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Denali Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Denali Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Denali Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Denali Therapeutics Inc?
plus_minus_icon
What percentage is Denali Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Denali Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$20.73
$-1.39
(-6.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00